Management of endocrine disease: pituitary tumour apoplexy

Capatina, Cristina, Inder, Warrick, Karavitaki, Niki and Wass, John A. H. (2015) Management of endocrine disease: pituitary tumour apoplexy. European Journal of Endocrinology, 172 5: R179-R190. doi:10.1530/EJE-14-0794


Author Capatina, Cristina
Inder, Warrick
Karavitaki, Niki
Wass, John A. H.
Title Management of endocrine disease: pituitary tumour apoplexy
Journal name European Journal of Endocrinology   Check publisher's open access policy
ISSN 1479-683X
0804-4643
Publication date 2015-05-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1530/EJE-14-0794
Open Access Status Not yet assessed
Volume 172
Issue 5
Start page R179
End page R190
Total pages 12
Place of publication Bristol, United Kingdom
Publisher BioScientifica
Collection year 2016
Language eng
Abstract Pituitary tumour apoplexy (PA) is a rare clinical syndrome that occurs as a result of acute haemorrhage and/or infarction within a frequently undiagnosed pituitary tumour. The sudden enlargement of the pituitary mass undergoing PA is responsible for a wide range of acute symptoms/signs (severe headache, visual loss, diplopia, hypopituitarism, impaired consciousness) which, together with the radiological evidence of a pituitary lesion, establish the diagnosis. The optimal care of PA requires involvement of a multidisciplinary team including endocrinologist, neurosurgeon, neuroophthalmologist and the management strategy that depends on the clinical manifestations, as well as the presence of co-morbidities. Prompt surgical decompression is initially indicated in cases with severe or progressive impairment of the visual acuity or the visual fields or with altered mental state and leads to visual and neurological recovery in most of the patients. The patients with mild, stable clinical picture (including those with isolated ocular palsies) can be managed conservatively (support of fluid and electrolyte balance and stress doses of steroids in most cases) with favourable visual and neurological outcome. Frequent reassessment is mandatory because the clinical course can be unpredictable; if progression of symptoms occurs, later elective surgery is indicated and is beneficial, especially in terms of visual outcome. The endocrinological outcome is less favourable, irrespective of the treatment option, with many patients remaining on long-term replacement therapy. Despite the above guidelines, clear proof of optimal outcomes in the form of randomised controlled trials is lacking. Regrowth of the pituitary tumour years after a PA episode is possible and patients require long-term surveillance.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2016 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 07 Jun 2015, 01:02:08 EST by System User on behalf of Scholarly Communication and Digitisation Service